Economic Evaluations in Systemic Lupus Erythematosus

Quintana, Gerardo; Bolivar, Helena Avella; Coral-Alvarado, Paola

doi:10.5772/39009

Cited by 1 publication

(3 citation statements)

References 20 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While other studies have examined increased health care use and expenditures in patients with SLE, 12,21 to the best of our knowledge, our study is the first to focus on patients with CLE and depression with a special emphasis on categories of health care use and expenditures. Because our study is believed to be the first to estimate health care expenditures associated with depression in CLE patients, we compared our estimates with previous estimates from studies conducted in SLE, and other rheumatic and skin diseases that have used similar methodology.…”

Section: Discussionmentioning

confidence: 99%

“…5,40 Finally, to our knowledge, this is the first study that estimates the incremental direct expenditures of depression in individuals with CLE in the USA. Some studies have estimated the incremental expenditures for SLE and other autoimmune diseases 12,13,21 using either the disease burden or cost-of-illness approach.…”

Section: Discussionmentioning

confidence: 99%

“…The economic burden on CLE is unknown, since most economic evaluations have been conducted in SLE. 12,13 For example, a 2013 study reported that patients with SLE had an average annual direct cost ranging from $2214 to $16,875 and an average annual productivity loss cost ranging from $2239 to $35,540. 13 While the prevalence of depression in SLE patients ranges from 30% to 45%, 14,15 little is known about the economic burden of depression in SLE patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Incremental health care services and expenditures associated with depression among individuals with cutaneous lupus erythematosus (CLE)

Ogunsanya

Nduaguba

Brown

2018

Lupus

View full text Add to dashboard Cite

Objectives The objective of this paper is to describe the annual direct medical expenditures for cutaneous lupus erythematosus (CLE) patients, and to estimate the incremental health care expenditures and utilization associated with depression among adults with CLE, while controlling for covariates. Methods Using the 2014 Medical Expenditure Panel Survey (MEPS), we compared CLE patients with and without depression to determine differences in: (a) health care utilization-inpatient, outpatient, office-based and emergency room (ER) visits, and prescriptions filled; and (b) expenditures-total costs, inpatient, outpatient, office-based, ER, and prescription medication costs, and other costs using demography-adjusted and comorbidity-adjusted multivariate models (age, gender, race/ethnicity, marital status, education, perception of health status, poverty category, smoking status, and Charlson Comorbidity Index). Results The total direct medical expenditure associated with CLE is estimated at approximately $29.7 billion in 2014 US dollars. After adjusting for covariates, adults with CLE and depression had more hospital discharges (utilization ratio (UR) = 1.13, 95% confidence interval (CI) (1.00-1.28)), ER visits (UR = 1.17, 95% CI (1.09-1.37)), and prescribed medicines (UR = 2.15, 95% CI (1.51-3.05)) than those without depression. Adults with CLE and depression had significantly higher average annual total expenditure that those without depression ($19,854 vs. $9735). Conclusions High health care expenditures are significant for patients with CLE, especially among those with depression. Prescription drugs, inpatient visits, and ER visits contributed most to the total expenditures in CLE patients with depression. Early diagnosis and treatment of depression in CLE patients may reduce total health care expenditures and utilization in this population.

show abstract

Section: Discussionmentioning

confidence: 99%